ATE317257T1 - Verwendung von estern von l-carnitinsäure oder von alkanoyl l-carnitinsäure als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe - Google Patents

Verwendung von estern von l-carnitinsäure oder von alkanoyl l-carnitinsäure als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe

Info

Publication number
ATE317257T1
ATE317257T1 AT03020049T AT03020049T ATE317257T1 AT E317257 T1 ATE317257 T1 AT E317257T1 AT 03020049 T AT03020049 T AT 03020049T AT 03020049 T AT03020049 T AT 03020049T AT E317257 T1 ATE317257 T1 AT E317257T1
Authority
AT
Austria
Prior art keywords
carnitic
alkanoyl
esters
acid
carnitic acid
Prior art date
Application number
AT03020049T
Other languages
English (en)
Inventor
Claudio Pisano
Maria Ornella Tinti
Mose Santaniello
Luciana Critelli
Giovanni Salvatori
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE317257T1 publication Critical patent/ATE317257T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT03020049T 1999-04-13 2000-04-11 Verwendung von estern von l-carnitinsäure oder von alkanoyl l-carnitinsäure als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe ATE317257T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti

Publications (1)

Publication Number Publication Date
ATE317257T1 true ATE317257T1 (de) 2006-02-15

Family

ID=11406659

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03020049T ATE317257T1 (de) 1999-04-13 2000-04-11 Verwendung von estern von l-carnitinsäure oder von alkanoyl l-carnitinsäure als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe
AT00922852T ATE286873T1 (de) 1999-04-13 2000-04-11 Ester des l-carnitin oder alkanoyl l-carnitin zur verwendung als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00922852T ATE286873T1 (de) 1999-04-13 2000-04-11 Ester des l-carnitin oder alkanoyl l-carnitin zur verwendung als kationische lipide für die intrazelluläre verabreichung therapeutischer stoffe

Country Status (34)

Country Link
US (4) US6797281B1 (de)
EP (3) EP1435232A1 (de)
JP (2) JP4703855B2 (de)
KR (2) KR100798499B1 (de)
CN (2) CN100402017C (de)
AT (2) ATE317257T1 (de)
AU (2) AU776301B2 (de)
BG (3) BG65501B1 (de)
BR (2) BRPI0017460B1 (de)
CA (2) CA2650202C (de)
CZ (1) CZ302628B6 (de)
DE (2) DE60025961T2 (de)
DK (2) DK1426044T3 (de)
EA (2) EA004459B1 (de)
EE (2) EE05719B1 (de)
ES (2) ES2258688T3 (de)
HK (2) HK1045145B (de)
HR (1) HRP20010740B1 (de)
HU (1) HU229366B1 (de)
IL (4) IL145765A0 (de)
IS (2) IS2476B (de)
IT (1) IT1306129B1 (de)
ME (2) ME00113B (de)
MX (1) MXPA01010359A (de)
NO (2) NO327742B1 (de)
NZ (2) NZ528874A (de)
PL (2) PL211710B1 (de)
PT (2) PT1183228E (de)
RS (3) RS20090448A (de)
SI (2) SI1183228T1 (de)
SK (2) SK287253B6 (de)
TR (2) TR200202358T2 (de)
WO (1) WO2000061543A2 (de)
ZA (1) ZA200109291B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246792B1 (de) * 2000-01-13 2014-08-13 Emisphere Technologies, Inc. Verbindungen und zusammensetzung zur abgabe von wirkstoffen
DE10113446A1 (de) 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
DK2108362T3 (da) * 2002-06-26 2013-09-02 Medigene Ag Kationisk liposomal-fremstilling omfattende en taxan
EP2108362B1 (de) * 2002-06-26 2013-05-29 MediGene AG Ein kationisches Trägersystem beinhaltend Taxane
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
US20080095834A1 (en) * 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CN101287448A (zh) * 2005-08-10 2008-10-15 诺瓦提斯公司 拓扑异构酶i的抑制剂7-叔丁氧基亚氨基甲基喜树碱的微粒组合物
WO2007017513A2 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
US20100178325A1 (en) * 2006-08-23 2010-07-15 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
AU2008210511A1 (en) * 2007-02-01 2008-08-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition comprising a campothecin derivative
US20100104625A1 (en) * 2007-02-16 2010-04-29 Cornell University Biodegradable compositions and materials
US20100204432A1 (en) 2007-05-28 2010-08-12 Husam Younes Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
ES2569660T3 (es) 2007-06-08 2016-05-12 Mannkind Corporation Inhibidores de la IRE-1alfa
EP2706121A1 (de) 2008-03-13 2014-03-12 PerkinElmer Health Sciences, Inc. Enzymatische Substrat Bauelementen zum Mehrfachdetektionssysteme
EP2532649B1 (de) * 2011-06-07 2015-04-08 Incella GmbH Aminolipide, deren Synthese und Verwendungen davon
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
CA2906839A1 (en) 2013-03-15 2014-09-18 Perkinelmer Health Sciences, Inc. Compounds and methods relating to testing for lysosomal storage disorders
MX2018010586A (es) 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.
EP3634942A4 (de) 2017-06-06 2021-03-10 Wayne State University Verfahren und zusammensetzungen in zusammenhang mit carnitin-abgeleiteten materialien
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
DE69119074T2 (de) * 1990-06-15 1996-12-12 University Of North Carolina At Chapel Hill, Chapel Hill, N.C. Kovalente-ther lipidnukleosid-konjugate
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
EP0706374B1 (de) * 1993-06-30 1997-12-10 Genentech, Inc. Verfahren zur herstellung von liposomen
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
AU707734B2 (en) * 1995-06-07 1999-07-15 Regents Of The University Of California, The Stabilization of polynucleotide complexes
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
WO1998004720A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
BG109876A (en) 2008-02-29
AU2004224958A1 (en) 2004-11-25
PT1426044E (pt) 2006-06-30
NO20014985D0 (no) 2001-10-12
EP1183228A2 (de) 2002-03-06
PL211710B1 (pl) 2012-06-29
HK1092732A1 (en) 2007-02-16
EA200101076A1 (ru) 2002-04-25
DK1426044T3 (da) 2006-06-12
DE60025961D1 (de) 2006-04-20
US20050079209A1 (en) 2005-04-14
IL145765A (en) 2007-07-04
ME00113B (me) 2010-10-10
IS8719A (is) 2008-03-07
DE60025961T2 (de) 2006-08-17
JP2011042657A (ja) 2011-03-03
AU2004224958B2 (en) 2007-11-22
HUP0201446A3 (en) 2002-11-28
CA2370143A1 (en) 2000-10-19
US6797281B1 (en) 2004-09-28
DK1183228T3 (da) 2005-05-17
KR20060113799A (ko) 2006-11-02
NO20014985L (no) 2001-10-12
DE60017388D1 (de) 2005-02-17
HK1045145B (zh) 2006-01-27
HRP20010740A2 (en) 2002-10-31
NZ528874A (en) 2005-09-30
ITRM990220A1 (it) 2000-10-13
CZ20013617A3 (cs) 2002-02-13
CN100402017C (zh) 2008-07-16
EE201100028A (et) 2011-08-15
EP1426044B1 (de) 2006-02-08
US20070190128A1 (en) 2007-08-16
EP1183228B1 (de) 2005-01-12
JP5420507B2 (ja) 2014-02-19
TR200202358T2 (tr) 2002-12-23
NO20085413L (no) 2001-10-12
HRP20010740B1 (en) 2005-08-31
YU70201A (sh) 2004-07-15
EE05514B1 (et) 2012-02-15
ATE286873T1 (de) 2005-01-15
JP2002541238A (ja) 2002-12-03
SI1183228T1 (en) 2005-04-30
HK1045145A1 (en) 2002-11-15
EE200100518A (et) 2002-12-16
CA2370143C (en) 2011-06-21
CA2650202C (en) 2012-12-11
IS2476B (is) 2008-12-15
IS6095A (is) 2001-09-28
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
BG105971A (en) 2002-08-30
HU229366B1 (en) 2013-11-28
AU776301B2 (en) 2004-09-02
ES2258688T3 (es) 2006-09-01
CZ302628B6 (cs) 2011-08-10
RS50911B (sr) 2010-08-31
NO327742B1 (no) 2009-09-14
SK287253B6 (sk) 2010-04-07
ZA200109291B (en) 2002-08-16
IL175366A0 (en) 2006-09-05
CN1263730C (zh) 2006-07-12
PL204418B1 (pl) 2010-01-29
WO2000061543A2 (en) 2000-10-19
BR0009765B1 (pt) 2013-11-05
BG65501B1 (bg) 2008-10-31
KR100684378B1 (ko) 2007-02-20
KR100798499B1 (ko) 2008-01-28
NO336949B1 (no) 2015-11-30
US7585519B2 (en) 2009-09-08
CN1359370A (zh) 2002-07-17
HUP0201446A2 (en) 2002-08-28
US7629003B2 (en) 2009-12-08
ES2234591T3 (es) 2005-07-01
IL175366A (en) 2010-12-30
BRPI0017460B1 (pt) 2016-04-19
CA2650202A1 (en) 2000-10-19
TR200102941T2 (tr) 2002-05-21
EE05719B1 (et) 2014-08-15
BR0009765A (pt) 2002-01-02
PT1183228E (pt) 2005-04-29
IS2539B (is) 2009-09-15
KR20010113794A (ko) 2001-12-28
BG65312B1 (bg) 2008-01-31
SI1426044T1 (sl) 2006-04-30
CN1823731A (zh) 2006-08-30
EA006021B1 (ru) 2005-08-25
EP1435232A1 (de) 2004-07-07
IT1306129B1 (it) 2001-05-30
DE60017388T2 (de) 2006-03-30
SK288246B6 (sk) 2015-03-03
EA004459B1 (ru) 2004-04-29
AU4312300A (en) 2000-11-14
RS52682B (en) 2013-08-30
IL145765A0 (en) 2002-07-25
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
EP1426044A1 (de) 2004-06-09
IL185486A0 (en) 2008-01-06
WO2000061543A3 (en) 2001-01-11
JP4703855B2 (ja) 2011-06-15
RS20090448A (en) 2010-06-30
MEP24008A (en) 2010-06-10
SK14312001A3 (sk) 2002-02-05
EA200300745A1 (ru) 2003-12-25

Similar Documents

Publication Publication Date Title
DE60025961D1 (de) Verwendung von Estern von L-Carnitinsäure oder von Alkanoyl L-Carnitinsäure als kationische Lipide für die intrazelluläre Verabreichung therapeutischer Stoffe
DE58905028D1 (de) Pharmazeutische kombinationspraeparate und deren verwendung als antineoplastische arzneimittel.
KR20160040627A (ko) 소포체
GR990100388A (el) Φαρμακευτικος συνδυασμος αποτελουμενος απο χωριστες δοσολογικες μορφες σε συσκευασια συμμορφωσης (compliance package) ενος αναστολεα της αναγωγασης του υδροξυ-μεθυλο-γλουταρυλο συνενζυμου α (στατινης, statin) και ενος παραγωγου του φιμπρικου οξεος....
EP0396081A3 (de) Verwendung von Phosphatidylcarnitin zur Herstellung von Arzneimitteln mit therapeutischer Wirkung auf mit neuronalen Schädigungen verbundenen pathologischen Zuständen beim Menschen
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
EP0761214A3 (de) N,N-disubstituierte Aniline oder Alkylamine als Löscher von Singulettsauerstoff; topische Zusammensetzungen, die sie enthalten
ATE272047T1 (de) Perfluorierte ester von alkanoyl l-carnitin zur herstellung von kationischen lipiden zur intrazellulären verabreichung pharmakologisch aktiver verbindungen
ATE190837T1 (de) Aminosäureergänzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1426044

Country of ref document: EP